| Untangling the ErbB signalling network Y Yarden, MX Sliwkowski Nature reviews Molecular cell biology 2 (2), 127-137, 2001 | 8732 | 2001 |
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate GD Lewis Phillips, G Li, DL Dugger, LM Crocker, KL Parsons, E Mai, ... Cancer research 68 (22), 9280-9290, 2008 | 1934 | 2008 |
| Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J Stamos, MX Sliwkowski, C Eigenbrot Journal of biological chemistry 277 (48), 46265-46272, 2002 | 1540 | 2002 |
| Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index JR Junutula, H Raab, S Clark, S Bhakta, DD Leipold, S Weir, Y Chen, ... Nature biotechnology 26 (8), 925-932, 2008 | 1441 | 2008 |
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex MC Franklin, KD Carey, FF Vajdos, DJ Leahy, AM De Vos, MX Sliwkowski Cancer cell 5 (4), 317-328, 2004 | 1400 | 2004 |
| Identification of Heregulin, a Specific Activator of p185erbB2 WE Holmes, MX Sliwkowski, RW Akita, WJ Henzel, J Lee, JW Park, ... Science 256 (5060), 1205-1210, 1992 | 1330 | 1992 |
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors AW Burgess, HS Cho, C Eigenbrot, KM Ferguson, TPJ Garrett, DJ Leahy, ... Molecular cell 12 (3), 541-552, 2003 | 1308 | 2003 |
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth DB Agus, RW Akita, WD Fox, GD Lewis, B Higgins, PI Pisacane, ... Cancer cell 2 (2), 127-137, 2002 | 1097 | 2002 |
| Treatment of HER2-positive breast cancer: current status and future perspectives CL Arteaga, MX Sliwkowski, CK Osborne, EA Perez, F Puglisi, L Gianni Nature reviews Clinical oncology 9 (1), 16-32, 2012 | 1056 | 2012 |
| Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates BQ Shen, K Xu, L Liu, H Raab, S Bhakta, M Kenrick, KL Parsons-Reponte, ... Nature biotechnology 30 (2), 184-189, 2012 | 1049 | 2012 |
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). MX Sliwkowski, JA Lofgren, GD Lewis, TE Hotaling, BM Fendly, JA Fox Seminars in oncology 26 (4 Suppl 12), 60-70, 1999 | 982 | 1999 |
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 TT Junttila, RW Akita, K Parsons, C Fields, GDL Phillips, LS Friedman, ... Cancer cell 15 (5), 429-440, 2009 | 966 | 2009 |
| Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. MX Sliwkowski, G Schaefer, RW Akita, JA Lofgren, VD Fitzpatrick, ... Journal of Biological Chemistry 269 (20), 14661-14665, 1994 | 915 | 1994 |
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers M Pegram, S Hsu, G Lewis, R Pietras, M Beryt, M Sliwkowski, D Coombs, ... Oncogene 18 (13), 2241-2251, 1999 | 892 | 1999 |
| HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. RJ Pietras, J Arboleda, DM Reese, N Wongvipat, MD Pegram, L Ramos, ... Oncogene 10 (12), 2435-2446, 1995 | 884 | 1995 |
| A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy ST Lee-Hoeflich, L Crocker, E Yao, T Pham, X Munroe, KP Hoeflich, ... Cancer research 68 (14), 5878-5887, 2008 | 749 | 2008 |
| Antibody therapeutics in cancer MX Sliwkowski, I Mellman Science 341 (6151), 1192-1198, 2013 | 694 | 2013 |
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer IE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ... J Clin Oncol 28 (16), 2698-2704, 2010 | 676 | 2010 |
| Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer TT Junttila, G Li, K Parsons, GL Phillips, MX Sliwkowski Breast cancer research and treatment 128, 347-356, 2011 | 609 | 2011 |
| Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin CD Austin, AM De Mazière, PI Pisacane, SM van Dijk, C Eigenbrot, ... Molecular biology of the cell 15 (12), 5268-5282, 2004 | 561 | 2004 |
